Research progress and current status of gene-edited-pig to non-human primate kidney xenotransplantation drug application

IF 1.4 4区医学 Q4 IMMUNOLOGY

Transplant immunology Pub Date : 2025-08-07 DOI:10.1016/j.trim.2025.102276

Shujun Yang , Hao Wei , Haihong Yang , Xilong Lin , Panfeng Shang , Shengkun Sun

{"title":"Research progress and current status of gene-edited-pig to non-human primate kidney xenotransplantation drug application","authors":"Shujun Yang , Hao Wei , Haihong Yang , Xilong Lin , Panfeng Shang , Shengkun Sun","doi":"10.1016/j.trim.2025.102276","DOIUrl":null,"url":null,"abstract":"<div><div>Kidney transplantation is the only effective treatment for patients with end-stage renal disease (ESRD). With the application of gene-editing technology and modern immunosuppressants, kidney transplants from pigs with up to 12 edited genes have shown significant survival in non-human primates (NHP) and have been transplanted in handful of patients. Our review describes the most current progress in gene-edited pigs used for kidney xenotransplantation (KXTx) to NHP. Furthermore, this review reports about drug treatment options such as immune induction, immune maintenance, anti-inflammatory therapy, and anticoagulant therapy aiming to provide in prospects of KXTx. We stress the following highlights: 1) The application of induction and maintenance therapies with gene edited pigs for NHP KXTx; 2) The application of CD40-CD154 co-stimulatory pathway blockers as essential in immune maintenance medication; 3) The role of cytokines in monitoring of anti-inflammatory treatment’ and 4) The salvage administration measures during suspected rejection reactions can to some extent prolong the functional survival of the recipient kidney.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"92 ","pages":"Article 102276"},"PeriodicalIF":1.4000,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transplant immunology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0966327425001042","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Kidney transplantation is the only effective treatment for patients with end-stage renal disease (ESRD). With the application of gene-editing technology and modern immunosuppressants, kidney transplants from pigs with up to 12 edited genes have shown significant survival in non-human primates (NHP) and have been transplanted in handful of patients. Our review describes the most current progress in gene-edited pigs used for kidney xenotransplantation (KXTx) to NHP. Furthermore, this review reports about drug treatment options such as immune induction, immune maintenance, anti-inflammatory therapy, and anticoagulant therapy aiming to provide in prospects of KXTx. We stress the following highlights: 1) The application of induction and maintenance therapies with gene edited pigs for NHP KXTx; 2) The application of CD40-CD154 co-stimulatory pathway blockers as essential in immune maintenance medication; 3) The role of cytokines in monitoring of anti-inflammatory treatment’ and 4) The salvage administration measures during suspected rejection reactions can to some extent prolong the functional survival of the recipient kidney.

查看原文本刊更多论文

基因编辑猪对非人灵长类动物肾脏异种移植药物应用的研究进展及现状。

肾移植是终末期肾病（ESRD）患者唯一有效的治疗方法。随着基因编辑技术和现代免疫抑制剂的应用，带有多达12个编辑基因的猪肾移植在非人灵长类动物（NHP）中显示出显着的存活率，并已移植到少数患者身上。我们的综述描述了用于肾异种移植（KXTx）到NHP的基因编辑猪的最新进展。此外，本文综述了药物治疗方案，如免疫诱导、免疫维持、抗炎治疗和抗凝治疗，旨在为KXTx的前景提供参考。我们强调以下重点：1)NHP KXTx基因编辑猪诱导和维持疗法的应用；2) CD40-CD154共刺激途径阻断剂在免疫维持药物中的应用；3)细胞因子在抗炎治疗中的监测作用；4)在疑似排斥反应时采取补救性给药措施，可在一定程度上延长受体肾脏的功能生存期。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Transplant immunology 医学-免疫学

CiteScore

2.10

自引率

13.30%

发文量

198

审稿时长

48 days

期刊介绍： Transplant Immunology will publish up-to-date information on all aspects of the broad field it encompasses. The journal will be directed at (basic) scientists, tissue typers, transplant physicians and surgeons, and research and data on all immunological aspects of organ-, tissue- and (haematopoietic) stem cell transplantation are of potential interest to the readers of Transplant Immunology. Original papers, Review articles and Hypotheses will be considered for publication and submitted manuscripts will be rapidly peer-reviewed and published. They will be judged on the basis of scientific merit, originality, timeliness and quality.